Melanoma Education: Progress Report
Two-thousand eighteen was a banner year for AIM at Melanoma and our education programs.
In July, AIM launched the Melanoma Learning Center (MLC), a one-stop shop and virtual hub for all types of melanoma education. MLC provides reliable, relevant, and current information about all aspects of melanoma for patients, families, health care professionals, caregivers, and others interested in the disease.
From thorough explanations of each stage of melanoma to thoroughly researched charts of known side effects of every drug used to treat melanoma, to treatment dosing calendars for melanoma patients, to information on clinical trials, there is information on MLC on every topic patients and caregivers might seek—and more. Information about AIM’s upcoming Living With Melanoma symposiums, the live streaming instructions for these symposiums, and all past symposium videos, are also available on MLC.
The Melanoma Learning Center has been the most visited portion of our website since its launch. We’re not surprised.
For those who treat melanoma patients, AIM provides a myriad of resources on our Melanoma Care website, a separate site for health care professionals. These resources include Continuing Medical Education offerings for both nurses and physicians; a professional online community to discuss melanoma patient care and treatment; and nursing care step pathways for patients on every type of melanoma treatment.
Our professional site has been used by health care providers in 49 states, the District of Columbia, and 108 countries, and it has been translated into 34 languages. So far in 2018, 4,325 doctors and nurses have taken our Continuing Medical Education course on melanoma therapeutics and side effect management.
But that’s not all that happened in 2018! Because of the success of our immunotherapy side effect care portion of the professional website, health care providers and industry partners reached out to AIM and asked that we create a similar site for all cancers. We agreed to take on this monumental task and launched AIM’s Cancer Immunotherapy Care website last month.
We accepted the challenge to create this new website because we realized that the vast majority of melanoma patients in the U.S. are cared for by community oncology professionals who would more likely visit a general immunotherapy site for patient care information than a melanoma-specific site.
So what is there left to do in 2019? A lot.
AIM’s latest education initiative is a 20-page booklet for Stage III patients that will help them sort through the large number of treatment pathways now available. Written with melanoma oncologists and nurses, this booklet will be available through AIM’s website and oncologists beginning in 2019.
Perhaps AIM’s most exciting new education project is our novel effort to partner with dermatologists and dermatology groups across the country to address a critical need in melanoma: educating dermatologists through Continuing Medical Education on how to give a thorough skin check, spot early melanomas, and appropriately refer patients to oncologists. We’ve found that most dermatologists are eager for this additional training and information. Just think: If we can reduce the number of late-stage melanomas by teaching dermatologists to find them earlier, we can reduce the number of deaths from melanoma. Now that is a worthy goal.
As always, we’ll keep you posted on this enormous project and all others, and let you know how you can help. On to 2019!